JOHN D. YOUNG - Corporate Board Profile

Johnson Controls International plc

Filing Date	Source Excerpt
2018-01-19	John D. Young Group president of Pfizer Innovative Health Age: 53 Director Since: 2017 Independent: Yes Committees: Audit Mr. Young became a director on December 7, 2017. No compensation reported for fiscal 2017.
2019-01-18	John D. Young Group President of Pfizer Innovative Health Age: 54 Director Since: 2017 Independent: Yes Current Committee Membership: Governance Director compensation for fiscal 2018 included $98,152 in fees earned or paid in cash and $193,750 in stock awards, totaling $291,902.
2020-01-17	John D. Young, Age 55 Director Since: December 2017 Independent: Yes Committee: Governance Director compensation for fiscal 2018 for non-employee Directors consisted of an annual cash retainer of $120,000 and restricted stock units (RSUs) with a grant date value of approximately $155,000 and a one-year vesting term. Beginning fiscal 2019, the annual cash retainer was increased to $140,000 and the grant date value of the annual RSU award was increased to $175,000. Mr. Young total compensation was $275,000.
2021-01-22	John D. Young, Age 56, Director Since: December 2017, Independent: Yes, Committee: Governance, Non-employee director compensation for fiscal 2020 consisted of an annual cash retainer of $140,000 and restricted stock units (RSUs) with a grant date value of approximately $175,000 and a one-year vesting term. Mr. Young total compensation $315,000.
2022-01-21	Mr. Young has served as Chief Business Officer of Pfizer Inc. since January 2019. ... Mr. Young also served as Pfizers Primary Care Business Units Regional President for Europe and Canada from 2009 until June 2012 and U.K. Country Manager from 2007 until 2009. ... Non-employee director compensation for fiscal 2021 consisted of an annual cash retainer of $140,000 and restricted stock units ("RSUs") with a grant date value of approximately $175,000 and a one-year vesting term.
2023-01-20	John D. Young, Age 58, Director Since: December 2017, Independent: Yes, Committee: Governance, Other Public Directorships: Arnivas, Inc., Haleon plc. Mr. Young served as Chief Business Officer of Pfizer Inc. He is a member of the Governance and Sustainability Committee. Non-employee Director compensation for fiscal 2022 consisted of an annual cash retainer of $140,000 and restricted stock units with a grant date value of approximately $175,000. Mr. Young received $140,000 in fees and $175,000 in stock awards totaling $315,000.
2024-01-19	John D. Young, Age 59, Director since 2018, Independent, Committee: Audit, Retired Chief Business Officer, Pfizer Inc.
2025-01-21	Mr. Young served as the Chief Business Officer of Pfizer Inc. from January 2019 until December 2021 and Special Advisor to the CEO from January 2022 until his retirement in July 2022. From January 2018 to December 2018, he served as Group President of Pfizer Innovative Health, and from June 2016 to January 2018 he served as Group President, Pfizer Essential Health. He was Group President, Global Established Pharma Business for Pfizer from January 2014 until June 2016 and President and General Manager, Pfizer Primary Care from June 2012 until December 2013. He also served as Pfizer’s Primary Care Business Unit’s Regional President for Europe and Canada from 2009 until June 2012 and U.K. Country Manager from 2007 until 2009. Mr. Young is currently a director of Arvinas, Inc., a clinical-stage biopharmaceutical company and Novartis AG, a multinational company specializing in the research, development, manufacturing and marketing of innovative pharmaceuticals and generic medicines.